EUROPEAN COMMISSION GRANTS MARKETING AUTHORISATION FOR NEZGLYAL® (LERIGLITAZONE), THE FIRST PHARMACOLOGICAL TREATMENT APPROVED FOR CEREBRAL ADRENOLEUKODYSTROPHY (CALD), A RARE NEURODEGENERATIVE DISEASE

Reuters · 2d ago

Please log in to view news